Advanced searches left 3/3

Colorectal Cancer - Zenodo

Summarized by Plex Scholar
Last Updated: 19 January 2023

* If you want to update the article please login/register

Formulation and Evaluation of Capecitabine Microspheres for Colorectal Cancer

Microspheres were created by emulsion solvent evaporation using polymers such as ethyl cellulose and HPMC K-I00 in various ratios. As the percentage of polymer ratio rises, it effects particle size, percentage yield, and drug release from the microspheres, according to the findings. The percentage yield of F6 microspheres was up to 95. 3 percent, according to the manufacturer. The first study was conducted with simulated intestinal fluid for 24 hours. Following a zero order, non-Fickian diffusion system, the optimized formulation F6 displayed the drug release in a sustained manner. No significant changes were made in percentage drug entrapment effectiveness, particle size, and in vitro controlled release of Capecitabine, according to the study. The surface morphology analysis formula F6 revealed a smooth surface morphology with smooth surface morphology. The prepared microspheres are intended to provide sustained oral therapy to the colon and a more kinetic profile with improved bioavailability.

Source link: https://zenodo.org/record/7534675


BBMRI-ERIC Colorectal Cancer Cohort (CRC-Cohort): Data Protection Policy

The Colorectal Cancer Cohort is produced by BBMRI-ERIC, its BBMRI-ERIC Na-tional/Organisational Nodes, and BBMRI-ERIC partner biobanks. After the conclusion of the trial in order to promote colorectal cancer research, the CRC-Cohort has been de-veloped as part of the ADOPT BBMRI-ERIC project1 and will become a permanent asset of the BBMRI-ERIC research infrastructure after the project's completion in order to enable re-search to improve treatment of the colorectal cancer treatment. Individual partner biobanks based on a joint data model developed and agreed on within the ADOPT BBMRI-ERIC program will be gathered for anonymized data, based on a standard data structure that was developed and agreed upon. This paper details the data privacy initiative that was introduced and is intended for the data security authorities supervising contributing partner biobanks and data privacy experts in ethics committees. In Section 5, a more in-depth review of a combination of technological and organizational steps to guarantee data integrity and protect privacy of the individuals contributing to CRC-Cohort is included.

Source link: https://zenodo.org/record/7513756


Patient-related data for colorectal cancer samples

In the ADOPT project, ADOPT BBMRI-ERIC Deliverable D2. 7 This Deliverable summarizes the progress and findings obtained during the collection of Colorectal Cancer Cohort, a Europe-wide initiative to gather a cohort of at least ten thousand colorectal cancer patients. A working group of medical and IT experts convened to create the common data model, tow the line between clearly defined data structures and providing sufficient data for meaningful medical research. The next steps included the establishment of the resulting data model in the common Metadata Repository, the implementation of a central data collection scheme called Colorectal Cancer Data Collection scheme, the design and implementation of data quality assurance tools to facilitate the migration process from common tabular files, design and implementation of data quality checks in collaboration between expert pathologists and IT experts, and finally, the data quality improvement cycle. In October 2017, the CRC-Cohort Data Privacy Policy was introduced and used in the dataset collection process. The central Colorectal Cancer Data Collection system was built based on open-source applications that were sufficiently extended to include the CRC-Cohort and to include either graphical user interface or an API for programmatic upload of data into the database. In addition, a scheme of data quality checks was created as a central service for the central database, with 70 different data checks focusing consistency and suspicious information. The agreement on data exchange was reached in compliance with the General Data Protection Regulation, with the IMI Code of Practice on Secondary Use of Medical Data in Scientific Research Projects, taking into account the differences in regulatory and ethical issues among the various European countries' different regions. The need for data quality checks was clear and will have to be addressed in future projects in which data remains in source repositories and therefore cannot be verified by the federated research infrastructure. Biobanks also need to be reminded that they will need to devote significant funds to continuous data quality enhancement, not just to primary data collection.

Source link: https://zenodo.org/record/7503731


Predicting the Stage of Colorectal Cancer Using Potential mRNA-Based Biomarker

Methods: A gene signature of 14 unique mRNAs was found using a benchmark database obtained from The Cancer Genome Atlas [1]. Using the GSE3232333 accession number, the gene set was then tested on a new dataset assembled using the Gene Expression Omnibus [2] method. Results: a training fidelity of 75% was achieved for the gene expression with a ROC-AUC score of 0. 81 for the TCGA dataset using an ensemble approach. Conclusion: The study confirmed the hypothesis and revealed a series of 14 unique mRNAs that can help determine the stage of Colorectal cancer in an individual.

Source link: https://zenodo.org/record/7460453

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions